Stockscreener 앱 받기
2.56
1.19%
0.03
시간 외 거래:
2.54
-0.02
-0.78%
Lipocine Inc 주식(LPCN)의 최신 뉴스
LPCN stock crashes 78%—here’s why - MSN
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Quarterly Risk: What is the Moat Score of Lipocine IncMarket Growth Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
What's going on with Lipocine stock on Monday? - MSN
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 - Investing.com UK
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 By Investing.com - Investing.com India
Director John Higuchi adds 40,000 Lipocine (LPCN) shares at $2.03 - Stock Titan
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock - Defense World
CEO Mahesh Patel Increases Stake in Lipocine Inc with Recent Sha - GuruFocus
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 By Investing.com - Investing.com Australia
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 - Investing.com
Director John W. Higuchi buys 123K Lipocine (LPCN) shares at $2.05 - Stock Titan
Lipocine CEO Patel acquires $50,749 in LPCN stock - Investing.com UK
Lipocine CEO Patel acquires $50,749 in LPCN stock By Investing.com - Investing.com India
Lipocine (LPCN) CEO adds 25,000 shares in stock purchase - Stock Titan
Lipocine adds to PPD setbacks as Tepezza scores, batoclimab misses in TED - biocentury.com
LPCN Downgraded to Neutral by HC Wainwright & Co. | LPCN Stock N - GuruFocus
What's Going On With Lipocine Stock On Monday? - Benzinga
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
H.C. Wainwright Downgrades Lipocine(LPCN.US) to Hold Rating - Moomoo
Lipocine Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Lipocine’s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation - timothysykes.com
Lipocine Faces Market Setback as LPCN 1154 Fails Key Trial - StocksToTrade
LPCN Should I Buy - Intellectia AI
Lipocine Stock Plummets After Clinical Trial Disappointment - StocksToTrade
Lipocine Updates Investor Presentation to Refine Market Messaging - The Globe and Mail
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm
Lipocine Inc (ticker: LPCN) announced that its experimental drug for postpartum depression failed to meet the primary endpoint in its Phase III clinical trial, causing the company's stock price to plummet by 78.4% in pre-market trading. - Bitget
Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning? - Bitget
LPCN | Lipocine Inc. Insider Trading - Quiver Quantitative
CEO Mahesh Patel Acquires 25,000 Shares of Lipocine Inc (LPCN) - GuruFocus
Lipocine CEO buys 25,000 shares in open market | LPCN Insider Trading - Stock Titan
Oral ‘roid void in PPD? Lipocine MINI bike may have wheels - BioWorld MedTech
LPCN Stock Crashes 78%— Here’s Why - Stocktwits
Lipocine weighs path after LPCN 1154 Phase 3 miss - TipRanks
Lipocine Reports Topline Safety and Efficacy Results for LPCN 11 - GuruFocus
[8-K] Lipocine Inc. Reports Material Event - Stock Titan
Phase 3 PPD trial for Lipocine (NASDAQ: LPCN) drug falls short - Stock Titan
Lipocine stock tumbles after phase 3 trial misses endpoint By Investing.com - Investing.com Australia
Lipocine stock tumbles after phase 3 trial misses endpoint - Investing.com
Lipocine's postpartum depression pill misses main goal in late-stage study - TradingView — Track All Markets
2.69%
0.25%
자본화:
|
볼륨(24시간):